Literature DB >> 30124761

Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention.

Sarah S Dermody1,2, Jeffery D Wardell2, Susan A Stoner3, Christian S Hendershot2,4,5,6.   

Abstract

Background: Adherence to medications for treating alcohol use disorder (AUD) is poor. To identify predictors of daily naltrexone adherence over time, a secondary data analysis was conducted of a trial evaluating a mobile health intervention to improve adherence.
Methods: Participants seeking treatment for AUD (n = 58; Mage = 38 years; 71% male) were prescribed naltrexone for 8 weeks. Adherence was tracked using the Medication Event Monitoring System (MEMS). In response to daily text messages, participants reported the previous day's alcohol use, craving, and naltrexone side effects. Using multilevel structural equation modeling (MSEM), we examined baseline dispositional factors and within-person, time-varying factors as predictors of daily adherence.
Results: Naltrexone adherence decreased over time. Adherence was higher on days when individuals completed daily mobile assessments relative to days when they did not (odds ratio [OR] = 2.53, 95% confidence interval [CI] 1.61 to 3.98), irrespective of intervention condition. Days when individuals drank more than their typical amount were related to lower next-day adherence (OR = 0.93, 95% CI 0.88 to 0.99). A similar pattern was supported for craving (OR = 0.88, 95% CI 0.79 to 0.98). Weekend days were associated with lower adherence than weekdays (OR = 0.71, 95% CI 0.58 to 0.86); this effect was partly mediated by heavier daily drinking (indirect effect = -0.02, 95% CI -0.04 to -0.003) and stronger-than-usual craving (indirect effect = -0.01, 95% CI -0.02 to 0.00) on weekend days. Conclusions: The results further demonstrate the need to improve adherence to AUD pharmacotherapy. The present findings also support developing interventions that target daily-level risk factors for nonadherence. Mobile health interventions may be one means of developing tailored and adaptive adherence interventions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30124761      PMCID: PMC6105286          DOI: 10.1093/abm/kax053

Source DB:  PubMed          Journal:  Ann Behav Med        ISSN: 0883-6612


  47 in total

1.  Test-retest reliability of alcohol measures: is there a difference between internet-based assessment and traditional methods?

Authors:  Elizabeth T Miller; Dan J Neal; Lisa J Roberts; John S Baer; Sally O Cressler; Jane Metrik; G Alan Marlatt
Journal:  Psychol Addict Behav       Date:  2002-03

2.  Alcohol dependence syndrome: measurement and validation.

Authors:  H A Skinner; B A Allen
Journal:  J Abnorm Psychol       Date:  1982-06

Review 3.  Measurement of alcohol craving.

Authors:  David J Kavanagh; Dixie J Statham; Gerald F X Feeney; Ross McD Young; Jon May; Jackie Andrade; Jason P Connor
Journal:  Addict Behav       Date:  2012-09-09       Impact factor: 3.913

4.  The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group.

Authors:  R S Croop; E B Faulkner; D F Labriola
Journal:  Arch Gen Psychiatry       Date:  1997-12

5.  Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial.

Authors:  Robert Miranda; Lara Ray; Alexander Blanchard; Elizabeth K Reynolds; Peter M Monti; Thomas Chun; Alicia Justus; Robert M Swift; Jennifer Tidey; Chad J Gwaltney; Jason Ramirez
Journal:  Addict Biol       Date:  2013-03-13       Impact factor: 4.280

Review 6.  A review of the literature on the cognitive effects of alcohol hangover.

Authors:  Richard Stephens; Jonathan Ling; Thomas M Heffernan; Nick Heather; Kate Jones
Journal:  Alcohol Alcohol       Date:  2008-01-31       Impact factor: 2.826

Review 7.  Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.

Authors:  Carmen Bouza; Magro Angeles; Angeles Magro; Ana Muñoz; José María Amate
Journal:  Addiction       Date:  2004-07       Impact factor: 6.526

8.  Risk factors for medication non-adherence among psychiatric patients with substance misuse histories.

Authors:  Stephen Magura; Pedro F Mateu; Andrew Rosenblum; Harlan Matusow; Chunki Fong
Journal:  Ment Health Subst Use       Date:  2014-11

Review 9.  Mental, neurological, and substance use disorders in people living with HIV/AIDS in low- and middle-income countries.

Authors:  Dixon Chibanda; Laura Benjamin; Helen A Weiss; Melanie Abas
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

10.  Improving adherence to antiretroviral therapy for youth living with HIV/AIDS: a pilot study using personalized, interactive, daily text message reminders.

Authors:  Nadia Dowshen; Lisa M Kuhns; Amy Johnson; Brian James Holoyda; Robert Garofalo
Journal:  J Med Internet Res       Date:  2012-04-05       Impact factor: 5.428

View more
  6 in total

Review 1.  Therapeutic efficacy of environmental enrichment for substance use disorders.

Authors:  Ewa Galaj; Eddy D Barrera; Robert Ranaldi
Journal:  Pharmacol Biochem Behav       Date:  2019-11-26       Impact factor: 3.533

2.  Current reporting of usability and impact of mHealth interventions for substance use disorder: A systematic review.

Authors:  Stephanie Carreiro; Mark Newcomb; Rebecca Leach; Simon Ostrowski; Edwin D Boudreaux; Daniel Amante
Journal:  Drug Alcohol Depend       Date:  2020-08-02       Impact factor: 4.492

3.  OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.

Authors:  Christian S Hendershot; Sarah S Dermody; Jeffrey D Wardell; Michelle J Zaso; James L Kennedy; Susan A Stoner
Journal:  Alcohol Clin Exp Res       Date:  2020-02-26       Impact factor: 3.455

4.  Veteran adherence to oral versus injectable AUD medication treatment.

Authors:  Hayden Stewart; Brian G Mitchell; Daniel Ayanga; Annette Walder
Journal:  Ment Health Clin       Date:  2021-05-12

Review 5.  The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder.

Authors:  Yann Chye; Erynn Christensen; Nadia Solowij; Murat Yücel
Journal:  Front Psychiatry       Date:  2019-02-19       Impact factor: 4.157

Review 6.  Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.

Authors:  Virginia Perez-Macia; Mireia Martinez-Cortes; Jesus Mesones; Manuel Segura-Trepichio; Lorena Garcia-Fernandez
Journal:  Patient Prefer Adherence       Date:  2021-05-18       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.